New pacemaker lead aims to improve heart function in bradycardia patients
NCT ID NCT06011252
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a special pacing lead placed in the left bundle branch area of the heart for people with symptomatic bradycardia (slow heartbeat). The goal is to see if this approach works well, is safe, and provides stable pacing over 12 months. About 134 adults who need a new pacemaker will take part, and researchers will monitor success rates, heart function, and any complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Solia S pacing lead with BIOTRONIK pacemaker
- What this could lead to
- If successful, this could offer a more effective and safer pacing method for people with slow heartbeats, reducing heart damage from traditional pacing.
- What could go wrong
- This is an early-stage, single-arm study with no comparison group, so results may not apply to all patients. The procedure carries standard risks like infection or lead displacement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYMPTOMATIC BRADYCARDIA are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chang Gung Memorial Hospital
Linkou District, Taipei, 10507, Taiwan
-
Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
-
China Medical University Hospital
Taichung, Taiwan
-
MacKay Memorial Hospital
Taipei, Taiwan
-
National Yang Ming Chiao Tung University Hospital
Yilan, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.